Archive for the ‘urology nephrology’ Category

Face, Content, And Construct Validity Of DV-trainer, A Novel Virtual Reality Simulator For Robotic Surgery

Posted by admin on Septiembre 10th, 2009 under urology nephrology
Tags: , ,  •  No Comments

UroToday.com The development of a virtual reality surgical simulator is an arduous process. Appropriate validation studies are critical to determining the appropriateness of the simulator as a teaching device and to assist in the continuous improvements and upgrades of the learning platform. In order to incorporate a simulator into an educational curriculum [...]

Potential New Therapy For Severe Kidney Disease Following Development of New Mouse Model

Posted by admin on Septiembre 2nd, 2009 under urology nephrology
Tags: ,  •  No Comments

Xlinked nephrogenic diabetes insipidus (XNDI) is a severe congenital kidney disease caused by mutations in the V2R gene. Currently, there is no effective drug to specifically treat XNDI, mainly because there are no good animal models of the disease. However, Jürgen Wess and colleagues, at the National Institute of Diabetes and Digestive and Kidney Diseases, [...]

Patients With Lower Urinary Tract Symptoms More Likely To Suffer From Metabolic Syndrome

Posted by admin on Junio 21st, 2009 under urology nephrology
Tags: ,  •  No Comments

Researchers have determined that individuals with mild to severe symptoms of lower urinary tract symptoms (LUTS) are more likely to suffer from metabolic syndrome (MetS), a collection of cardiovascular risk factors thought to be linked by insulin resistance). LUTS encompass voiding (incomplete emptying, weak stream, intermittency, straining) and storage (frequency, urgency, nocturia) difficulties.
In [...]

Mayo Genomic Discovery: Protecting Kidney Function During Heart Failure

Posted by admin on Junio 17th, 2009 under urology nephrology
Tags: , ,  •  No Comments

Mayo Clinic cardiology researchers have found a peptide that helps preserve and improve kidney function during heart failure, without affecting blood pressure. Earlier variations of this peptide caused blood pressure to drop limiting the potential benefits to the kidneys. The findings appear in the current Proceedings of the National Academy of Sciences.
“Heart failure itself and [...]

AEterna Zentaris To Report Data From Safety Study Of Phase 3 Program In Benign Prostatic Hyperplasia With Cetrorelix Ahead Of Schedule

Posted by admin on Junio 16th, 2009 under urology nephrology
Tags: ,  •  No Comments

AEterna Zentaris Inc. (NASDAQ AEZS; TSX AEZ), a global biopharmaceutical company focused on endocrine therapy and oncology, reported that patient followup in the openlabel safety study (study 041) of its Phase 3 program in benign prostatic hyperplasia (BPH) with its lead endocrinology compound, cetrorelix pamoate, is scheduled to be completed at the end of [...]

GTxs Toremifene 80 Mg Increased Bone Mineral Density In Multiple Clinically Relevant Subpopulations Of Prostate Cancer Patients

Posted by admin on Junio 3rd, 2009 under urology nephrology
Tags: ,  •  No Comments

GTx, Inc. (Nasdaq GTXI) announced the presentation of data demonstrating that toremifene 80 mg treatment compared to placebo increased bone mineral density (BMD) in multiple clinically relevant subpopulations of men with prostate cancer on androgen deprivation therapy (ADT). The data, an analysis of results of the recent Phase III clinical trial evaluating toremifene 80 mg [...]

First Choice Of Renal Function Tests In Hepatectomy Patients

Posted by admin on Mayo 25th, 2009 under urology nephrology
Tags: , ,  •  No Comments

Although creatinine clearance (Ccr) has been measured clinically by a simple method as a preoperative renal function test, Ccr is not strictly equal to glomerular filtration rate (GFR). Recently, an equation for estimated GFR (eGFR) for Japanese individuals has been postulated, and eGFR has been accepted as equal to measured GFR in chronic kidney disease. [...]